Galena Biopharma, Inc. (GALE) belonging to the Medical sector has surged 0.85% and closed its last trading session at $0.63.
The company reported its EPS on 03/16/2017. Currently, the stock has a 1 Year Price Target of $8.
The consensus recommendation, according to Zacks Investment research, is 3. The scale runs from 1 to 5 with 1 recommending Strong Buy and 5 recommending a Strong Sell.
The Stock had a 3 Consensus Analyst Recommendation 30 Days Ago, whereas 60 days ago and 90 days ago the analyst recommendations were 2 and 2 respectively.
Galena Biopharma, Inc. on 03/16/2017 reported its EPS as $-0.49 with the analysts projecting the EPS of the stock as $-0.52. The company beat the analyst EPS Estimate with the difference of $0.03. This shows a surprise factor of 5.8%.
Many analysts have provided their estimated foresights on Galena Biopharma, Inc. Earnings, with 2 analysts believing the company would generate an Average Estimate of $-0.22.
Whereas they predicted High and Low Earnings Estimate as $-0.21 and $-0.22 respectively. While in the same Quarter Previous year, the Actual EPS was $-1.8.
For the Current Quarter, the growth estimate for Galena Biopharma, Inc. is 87.8%, while for the Next Quarter the stock growth estimate is -128.3%.
The Company got Downgrade by FBR & Co. on 6-Feb-17 from Outperform to Mkt Perform.
Insider Trades for Galena Biopharma, Inc. show that the latest trade was made on 7 Feb 2017 where Hudson Bay Capital Management, L.P., the Beneficial Owner of More than 10% Class completed a transaction type “Sell” in which 2363441 shares were traded at a price of $0.84.
1 analysts projected Price Targets for Galena Biopharma, Inc.. The analysts believe that the company stock price could grow as high as $8. The Low Price target projection by analysts is $8 and the Mean Price Target is $8.
Galena Biopharma, Inc. (GALE) has the market capitalization of $22.51 Million. The company rocked its 52-Week High of $4.75 on Nov 21, 2016 and touched its 52-Week Low of $0.16 on Nov 9, 2016.
The stock has Return on Assets (ROA) of -33.8 percent. Return on Equity (ROE) stands at -110.4% and Return on Investment (ROI) of 0 percent.
The stock is currently showing YTD performance of -67.77 Percent. The company has Beta Value of 1.54 and ATR value of 0.08. The Weekly and Monthly Volatility stands at 14.33% and 8.85%.